| Prev Close | 107.97 |
| Open | 109.00 |
| Day Low/High | 108.00 / 112.04 |
| 52 Wk Low/High | 92.56 / 141.86 |
| Volume | 1.81M |
| Avg Volume | 2.24M |
Alexion Pharmaceuticals Inc. (ALXN)
110.65
2.70
2.50
NASDAQ : Health Technology
| Exchange | NASDAQ |
| Shares Outstanding | 221.29M |
| Market Cap | 23.98B |
| EPS | 0.30 |
| P/E Ratio | 7.69 |
| Div & Yield | N.A. (N.A) |
Latest News
Here Are Several Promising Rare Disease Stocks
These small biotech concerns are undervalued.
I'm Unapologetically Overweight in These 2 Sectors
The two are homebuilding and biotech, and there are stocks within those sectors where I've parked my money.
3 Biotech Plays That Would Work as Covered Calls
The SPDR S&P Biotech ETF, Alexion Pharmaceuticals and BioMarin Pharmaceuticals set up nicely for this options strategy.
A Sagging Drugmaker and Lagging Pet Health Name Both Worth Looks
Alexion Pharmaceuticals and Elanco Animal Health have seen their shares go to the dogs of late, but still offer reasons for portfolio consideration.
Otezla Price Under Microscope -- but Look Closely and It Checks Out
Sure, Celgene, in its tie-up with Bristol-Myers Squibb, had to sell to meet merger requirements, but look at the future pay off for Amgen.
M&A Appetite in Pharma Has Proved Potent: Chart of the Day
With total deals trending toward hundreds of billions, investors may be eager to bet on who's next to be acquired.
Amgen Adds Celgene's Otezla to Bolster Pipeline at Pricey Valuation
Amgen is finally making an expected splash out of its cash pile, but questions are abounding about the cost paid for Celgene's Otezla.
A Pair of Rare Disease Biotech Concerns Worth a Good Look
Alexion Pharmaceuticals is a solid company that is the subject of acquisition rumors and Amicus Therapeutics has a key drug off to a strong start.
5 Favorites for Biotech Stock Buyers
For those with a long-term horizon, here are some top picks.
A Handful of Small Biotechs That Make for Merger Chatter
The names include a veterinary drug concern plus companies with successful drugs on the market.
A Six-Pack of Biotech Best Bets
Ironically, some experts now see biotech as a safe haven as the sector remains unaffected by trade wars and other global headwinds.
Roche Deal for Spark Therapeutics Shows Biotech M&A Spark Hasn't Died
Acquisition deals for biotech companies at the start of 2019 are giving the sector a nice boost; here are other names that could be merger candidates.
Two Small-Caps and One Mid-Cap Stock I Like So Far in 2019
It has been a better year for the Russell 2000 and the small-caps it represents.
New Year's Investing Resolutions
The market's day-to-day extreme volatility tested even the most seasoned investors. Adhering to portfolio principles can help.
Jim Cramer: These Are the Stocks to Buy on Canada Deal and the 4th Quarter
Straying from these names could land you in quicksand as the 4th quarter begins.
Another Day of Rotation, but of a Different Sort
Big-cap FAANG names and Apple, in particular, were the beneficiaries.
Here's My Take on Biotech Stocks
I think M&A activity will pick up markedly going forward across the industry.
Three Biotech Names to Consider
A look at three names to consider in the biotech and biopharma space.
Getting Ready for Biotech Earnings
Now that M&A is picking up in the sector, here's what to watch as earnings releases begin to hit.
7 Hot Investing Bets to Make in Biotech
These favorite names in the volatile sector offer the potential for high rewards.
Sage Therapeutics Skyrockets on Data for Depression Drug -- Biotech Movers
The Cambridge, Mass.-based firm unveiled positive top-line results from its Phase 2 study of SAGE-217 in patients with moderate to severe major depressive disorder.
10 Biotech Stocks Investors Should Put on Their Shopping List for 2018
Biotech M&A activity will pick up markedly in 2018, and these companies are likely to be the most active in that space.
10 Biotech Stocks to Watch in 2018
There are a variety of players that should be active in the M&A space next year.
Alexion Suffers Quantitative Downgrade, Bearish Charts
The path of least resistance is downward for Alexion.
Alexion Pops After Securing FDA Nod for Myasthenia Gravis Drug -- Biotech Movers
The New Haven, Conn.-based firm said Monday it has secured approval from the U.S. Food and Drug Administration for Soliris (eculizumab) as a treatment for adults with generalized myasthenia gravis (gMG) that are anti-acetylcholine receptor (AChR) antibody-positive.
